莫西沙星治疗非淋菌性尿道(宫颈)炎86例疗效分析

Analysis of moxifloxacin in 86 patients with nongonococcal urethritis(cervicitis)

目的观察莫西沙星治疗泌尿生殖系支原体和衣原体感染的临床疗效和安全性。方法将86例非淋菌性尿道(宫颈)炎(NGU)患者分为两组:A组为CT和(或)Uu感染引起的NGU组;B组是莫西沙星治疗耐喹诺酮类药物支原体感染所致NGU组。两组均口服莫西沙星400mg,每日1次,疗程12d,并观察临床疗效及不良反应。结果A、B组临床痊愈率和总有效率分别为83%、93%,74%、83%。未发生严重不良反应,不良反应发生率为8.14%。结论莫西沙星是一种治疗NGU有效、安全、服用方便的抗菌药物。

Objective To study the efficacy and safety of rnoxifloxacin monotherapy in 86 patients with nongonococcal urethritis （cervicitis）. Methods The patients were divided into two groups. Group A was chlamydia trachomatis and/or mycoplasma infectious group,and group B was quinolones resistance in treating mycoplasma infections. Eighty-six patients were received a 12d course of oral moxifloxacin,400 mg once daily. The efficacy and safety were evaluated. Results The clinical recovery rates and total effective rates for group A were 83%and 93% ,and 74% and 83% for group B,respectively. The drug related adverse events occurred at 8.14% and no severe adverse reaction was observed. Conclusion Moxifloxacin therapy was clinically effective,safe and convenient in treating nongonococcal urethritis （cervicitis）.